Janus Henderson Group PLC Takes $15.02 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Janus Henderson Group PLC acquired a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 636,231 shares of the company’s stock, valued at approximately $15,018,000. Janus Henderson Group PLC owned approximately 0.71% of NewAmsterdam Pharma as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Wolverine Asset Management LLC raised its stake in shares of NewAmsterdam Pharma by 197.2% during the 4th quarter. Wolverine Asset Management LLC now owns 8,694 shares of the company’s stock worth $97,000 after acquiring an additional 5,769 shares in the last quarter. Yarbrough Capital LLC acquired a new position in NewAmsterdam Pharma during the 1st quarter valued at approximately $567,000. Parkman Healthcare Partners LLC increased its stake in NewAmsterdam Pharma by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock valued at $3,359,000 after purchasing an additional 51,726 shares in the last quarter. StemPoint Capital LP acquired a new position in NewAmsterdam Pharma during the 1st quarter valued at approximately $1,900,000. Finally, Baker BROS. Advisors LP acquired a new position in NewAmsterdam Pharma during the 1st quarter valued at approximately $2,290,000. Institutional investors own 89.89% of the company’s stock.

Insider Activity

In other NewAmsterdam Pharma news, CEO Michael H. Davidson bought 5,000 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, June 20th. The stock was acquired at an average cost of $17.26 per share, for a total transaction of $86,300.00. Following the completion of the transaction, the chief executive officer now directly owns 204,784 shares of the company’s stock, valued at $3,534,571.84. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 19.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on NAMS shares. Royal Bank of Canada restated an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday. TD Cowen started coverage on shares of NewAmsterdam Pharma in a report on Wednesday, May 15th. They issued a “buy” rating on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $33.25.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS opened at $17.12 on Thursday. The company’s fifty day moving average price is $19.09 and its 200 day moving average price is $20.40. NewAmsterdam Pharma has a 1 year low of $5.63 and a 1 year high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.08). The business had revenue of $1.40 million for the quarter, compared to analyst estimates of $2.95 million. As a group, analysts anticipate that NewAmsterdam Pharma will post -2.24 earnings per share for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.